TLR3 and neoplasm: Wang et al. used polypeptide hydrogel loaded with tumor cell lysates (TCL) as antigens, Toll-like receptors 3 (TLR3) agonist, polyinosinic:polycytidylic acid [poly(I:C)] to construct the vaccines, which robustly recruit, activate and mature DCs in vitro and in vivo by sustained release of TCL and poly (I:C).